Immunome Ownership
| IMNM Stock | USD 9.04 0.27 3.08% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 60 M | Current Value 60 M | Avarage Shares Outstanding 16.4 M | Quarterly Volatility 18.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Immunome |
Immunome Stock Ownership Analysis
About 19.0% of the company shares are held by company insiders. The book value of Immunome was currently reported as 3.56. The company recorded a loss per share of 7.94. Immunome had not issued any dividends in recent years. Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. Immunome operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. To learn more about Immunome call Purnanand Sarma at 610 321 3700 or check out https://immunome.com.Besides selling stocks to institutional investors, Immunome also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Immunome's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Immunome's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Immunome Quarterly Liabilities And Stockholders Equity |
|
Immunome Insider Trades History
About 19.0% of Immunome are currently held by insiders. Unlike Immunome's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Immunome's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Immunome's insider trades
Immunome Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunome is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunome backward and forwards among themselves. Immunome's institutional investor refers to the entity that pools money to purchase Immunome's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jefferies Financial Group Inc | 2024-12-31 | 2 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-12-31 | 1.2 M | Woodline Partners Lp | 2024-12-31 | 980.9 K | Sofinnova Ventures | 2024-12-31 | 746.8 K | Point72 Asset Management, L.p. | 2024-12-31 | 688.8 K | Jpmorgan Chase & Co | 2024-12-31 | 648.6 K | Northern Trust Corp | 2024-12-31 | 516.5 K | Adage Capital Partners Gp Llc | 2024-12-31 | 500 K | T. Rowe Price Investment Management,inc. | 2024-12-31 | 5.5 M | Redmile Group, Llc | 2024-12-31 | 4.8 M |
Immunome Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunome insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunome's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunome insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunome Outstanding Bonds
Immunome issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunome uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunome bonds can be classified according to their maturity, which is the date when Immunome has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Immunome Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
| 4th of February 2025 Other Reports | ViewVerify | |
| 3rd of February 2025 Other Reports | ViewVerify | |
| 30th of January 2025 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share | Quarterly Revenue Growth (0.18) | Return On Assets | Return On Equity |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.